• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 28, 2014

View Archived Issues

Masked antibodies with cash: BMS inks immuno-oncology deal with Cytomx

Bristol-Myers Squibb Co. is paying $50 million for rights to use Cytomx Therapeutics Inc.'s Probody platform to discover and develop up to four new immunotherapies for cancer, including one targeting CTLA-4, the same receptor targeted by BMS' melanoma fighter, Yervoy (ipilimumab). Read More

Spark ignites interest in gene therapy pipeline with $72.8M series B

Spark Therapeutics Inc., which burst on the gene therapy scene last October, lit a fire under a syndicate of investors that plowed $72.8 million into a series B just seven months after the company's launch. Read More

In a rare defeat for Pfizer, Astrazeneca offer fizzles

LONDON – Monday's deadline of 5 p.m. London time passed without Pfizer Inc. making a further move for Astrazeneca plc, meaning any fresh approach – from Pfizer at least – is off the table for six months. Read More

Wine corker: OPuS-1 bid wins for Biocryst in HAE, Dyax sips from phase IIa

Top-line success for Biocryst Pharmaceuticals Inc. in a phase IIa proof-of-concept trial called OPuS-1 (Oral ProphylaxiS-1) with oral kallikrein inhibitor BCX4161 against hereditary angioedema (HAE) brought competitor Dyax Corp. along for the ride, as backers of both companies guessed about what's in store for the busy therapeutic space. Read More

Asian biopharmas eye biosimilars opportunities through regulatory weed

SHANGHAI – At the 5th Annual Biosimilars Asia conference held here, a varied mix of Asian biosimilar developers and the consultants that advise them were on hand to discuss the commercial opportunity for biosimilars, if one can only figure out the numerous and costly challenges first. Read More

Leem confronts French drug pricing cuts

In the coming weeks, Leem, the French pharmaceutical industry lobby group, will present compromise proposals to Social Affairs and Health Minister Marisol Touraine, in an effort to stave off what the group regards as draconian cuts to the country's drugs bill. Read More

New CFDA penalties emphasizing due process effective June 1

HONG KONG – The CFDA's new rules covering food, drugs and medical devices give the accused the chance to petition for a hearing and outline the investigative path authorities must follow, including the use of evidence from outside of the country, before levying penalties that range from fines to shutting operations. Read More

Macrogenics draws Takeda to potential $500M alliance

Macrogenics Inc. enticed another big pharma partner to the table with a candidate from its Dual-Affinity Re-Targeting, or DART platform. Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, took an option to develop and commercialize MGD010, a preclinical asset targeting autoimmune diseases, that uses DART to simultaneously engage the B-cell surface proteins CD32B and CD79B. Read More

News from Washington

The FDA has cleared its backlog of paper adverse event reports. By adding additional data entry staff and re-engineering its process, the agency has entered all the backlogged paper reports into the FDA's Adverse Event Reporting System (FAERS) database. Read More

Other news to note

Bioinvent International AB, of Lund, Sweden, said it sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience AB, also of Lund, Sweden, for an undisclosed sum. Read More

Stock movers

Read More

In the clinic

Immune Design Corp., of Seattle, said the application of its GLAAS discovery platform is being used in the phase I trial of MEDI7510, an investigational agent for respiratory syncytial virus (RSV) in development by the Medimmune arm of London-based Astrazeneca plc. Read More

Pharma: Other news to note

Abiogen Pharma SpA, of Pisa, Italy, said it granted Lee's Pharmaceutical Ltd., of Hong Kong, the license, distribution and marketing of Attila (neridronic acid) throughout China, Hong Kong, Macau and Taiwan for the two orphan/rare disease indications osteogenesis imperfecta and complex regional pain syndrome. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe